FindTrial
Sign In

Impact of Pharmaceutical care on hypothyroid patients with metabolic syndrome

IMPACT OF CLINICAL PHARMACY SERVICES ON THERAPEUTIC OUTCOMES AND QUALITY OF LIFE IN HYPOTHYROID PATIENTS WITH METABOLIC SYNDROME

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046317
Enrollment
200
Registered
2022-10-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E039- Hypothyroidism, unspecified

Interventions

Intervention1: Interventional trial-Randomized controlled trial: The study population includes hypothyroid patients with metabolic syndrome. The Principal Investigator will provide interventions such

Sponsors

Dr Bipin Shaji
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 years and above of both gender, diagnosed with Hypothyroidism with metabolic syndrome [based on Modified National Cholesterol Education Program Adult Treatment Panel III (Modified NCEP ATP III) criteria] will be enrolled in the study. The study includes both Inpatients and Outpatients.

Exclusion criteria

Exclusion criteria: Pregnant women, Type I Diabetic Mellitus, and Cancer patients

Design outcomes

Primary

MeasureTime frame
Improvement in the Health-Related Quality of life in Hypothyroid patients with metabolic syndromeTimepoint: Baseline, 6 months, 12 months—

Secondary

MeasureTime frame
Improvement in the Medication adherence and therapeutic outcomes, economic outcomesTimepoint: Baseline, 6 months, 12 months—

Countries

India

Contacts

Public ContactDr Juno J Joel

KS Hegde Medical Academy

rrsharma1967@gmail.com9448770919

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026